REFRACTORY PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for REFRACTORY PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for REFRACTORY PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo tested to fight aggressive blood cancer
Disease control OngoingThis study is testing a combination of two drugs, pembrolizumab and romidepsin, for people with a type of blood cancer called peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if using these drugs together is safe and mor…
Matched conditions: REFRACTORY PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for patients with aggressive lymphoma that Won't respond
Disease control OngoingThis study is testing two drugs, durvalumab and lenalidomide, to see if they can help control advanced T-cell lymphomas that have come back or stopped responding to other treatments. It aims to find the safest dose and see how well the drugs work, either alone or together, for pa…
Matched conditions: REFRACTORY PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC